[A meta-analysis of the efficacy and safety of the anti-obesity agent Rimonabant].
A meta-analysis of all randomised controlled trials examining the efficacy and safety of the anti-obesity agent Rimonabant (Acomplia, 20 mg/d) found an efficacy of 4.7 kg (4.1-5.3) more weight loss after one year compared to placebo. Rimonabant increased the risk of adverse events, including depressive episodes and anxiety, despite depressive symptoms being an exclusion criterion in these trials. This, combined with an increased risk of suicidality during Rimonabant treatment, warrants increased awareness from prescribing physicians.
Christensen
Robin
R
Frederiksberg Hospital, Parker Instituttet, Københavns Universitet, Det Biovidenskabelige Fakultet, Institut for Human Ernaering, Frederiksberg C.
Kristensen
Pernelle Kruse
PK
Bartels
Else Marie
EM
Bliddal
Henning
H
Astrup
Arne V
AV